NYSE:GEN - Genesis HealthCare Stock Price, Price Target & More

Get Started

$2.14 -0.01 (-0.47 %)

(As of 05/23/2018 12:56 PM ET)

Previous Close$2.10

Today's Range$2.05 - $2.24

52-Week Range$0.60 - $2.19

Volume12,876 shs

Average Volume533,666 shs

Market Capitalization$317.30 million

P/E Ratio-1.02

Dividend YieldN/A

Beta0.9

About Genesis HealthCare (NYSE:GEN)

Genesis Healthcare, Inc. is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services.

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Skilled nursing care facilities

Sub-IndustryN/A

SectorMedical

SymbolNYSE:GEN

CUSIPN/A

Webwww.genesishcc.com

Phone610-444-6350

Debt

Debt-to-Equity Ratio-2.80

Current Ratio1.11

Quick Ratio1.11

Price-To-Earnings

Trailing P/E Ratio-1.02

Forward P/E Ratio-1.54

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.37 billion

Price / Sales0.06

Cash Flow$2.8158 per share

Price / Cash0.76

Book Value($11.21) per share

Price / Book-0.19

Profitability

EPS (Most Recent Fiscal Year)($2.11)

Net Income$-578,980,000.00

Net Margins-11.29%

Return on EquityN/A

Return on Assets-2.73%

Miscellaneous

Employees68,700

Outstanding Shares159,450,000

Genesis HealthCare (NYSE:GEN) Frequently Asked Questions

What is Genesis HealthCare's stock symbol?

Genesis HealthCare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."

How were Genesis HealthCare's earnings last quarter?

Genesis HealthCare (NYSE:GEN) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.34. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the firm posted ($0.55) EPS. View Genesis HealthCare's Earnings History.

What price target have analysts set for GEN?

4 equities research analysts have issued 12-month price targets for Genesis HealthCare's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Genesis HealthCare's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for Genesis HealthCare.

Who are some of Genesis HealthCare's key competitors?

Some companies that are related to Genesis HealthCare include Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Biohaven Pharmaceutical (BHVN), WAVE Life Sciences (WVE), Cellectis (CLLS), Amneal Pharmaceuticals (AMRX), Luminex (LMNX), Intra-Cellular Therapies (ITCI), Glaukos (GKOS), Apellis Pharmaceuticals (APLS), U.S. Physical Therapy (USPH), Intersect ENT (XENT), Accelerate Diagnostics (AXDX), Epizyme (EPZM) and Mayne Pharma Group (MYX).

Who are Genesis HealthCare's key executives?

Genesis HealthCare's management team includes the folowing people:

Robert H. Fish, Chairman of the Board
George V. Hager Jr., Chief Executive Officer, Director
Thomas DiVittorio, Chief Financial Officer
Paul David Bach, Chief Operating Officer
Jeanne Phillips, Chief Human Resource Officer, Senior Vice President
, Bio & Compensation -
David C. Almquist, Executive Vice President, President - West and East Divisions
Richard P. Blinn, Executive Vice President, President - Northeast Division and Southeast Divisions
JoAnne Reifsnyder Ph.D., Executive Vice President - Clinical Operations, Chief Nursing Officer
Richard L. Castor, Senior Vice President, Chief Information Officer
Michael S. Sherman, Senior Vice President, General Counsel, Assistant Treasurer, Secretary

Has Genesis HealthCare been receiving favorable news coverage?

News coverage about GEN stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genesis HealthCare earned a news sentiment score of 0.17 on Accern's scale. They also assigned news articles about the company an impact score of 47.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Genesis HealthCare's major shareholders?

Genesis HealthCare's stock is owned by a number of of institutional and retail investors. Top institutional investors include Columbia Pacific Advisors LLC (3.86%), First Washington CORP (1.88%), V3 Capital Management L.P. (1.60%), BlackRock Inc. (1.44%), Glassman Wealth Services (0.70%) and Prescott Group Capital Management L.L.C. (0.37%). Company insiders that own Genesis HealthCare stock include Daniel Allen Hirschfeld, George V Hager Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Institutional Ownership Trends for Genesis HealthCare.

Which institutional investors are selling Genesis HealthCare stock?

GEN stock was sold by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Columbia Pacific Advisors LLC, JPMorgan Chase & Co., First Washington CORP, Forward Management LLC and Northern Trust Corp. Company insiders that have sold Genesis HealthCare company stock in the last year include Daniel Allen Hirschfeld, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Insider Buying and Selling for Genesis HealthCare.

Which institutional investors are buying Genesis HealthCare stock?

GEN stock was purchased by a variety of institutional investors in the last quarter, including Glassman Wealth Services, V3 Capital Management L.P., BlackRock Inc., Schwab Charles Investment Management Inc., Millennium Management LLC, California Public Employees Retirement System and BSW Wealth Partners. View Insider Buying and Selling for Genesis HealthCare.

How do I buy shares of Genesis HealthCare?

Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genesis HealthCare's stock price today?

One share of GEN stock can currently be purchased for approximately $2.19.

How big of a company is Genesis HealthCare?

Genesis HealthCare has a market capitalization of $317.30 million and generates $5.37 billion in revenue each year. The company earns $-578,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Genesis HealthCare employs 68,700 workers across the globe.

How can I contact Genesis HealthCare?

Genesis HealthCare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]

MarketBeat Community Rating for Genesis HealthCare (GEN)

Community Ranking:		2.0 out of 5 ( )
Outperform Votes:		154 (Vote Outperform)
Underperform Votes:		225 (Vote Underperform)
Total Votes:		379

MarketBeat's community ratings are surveys of what our community members think about Genesis HealthCare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Genesis HealthCare (NYSE:GEN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Genesis HealthCare in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible downside of 6.54%. The high price target for GEN is $2.00 and the low price target for GEN is $2.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.25	2.33	2.50	2.50
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$2.00	$2.00	$2.00	$2.00
Price Target Upside:	6.54% downside	30.72% upside	96.08% upside	96.08% upside

Genesis HealthCare (NYSE:GEN) Consensus Price Target History

Price Target History for Genesis HealthCare (NYSE:GEN)

Genesis HealthCare (NYSE:GEN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2018	Stifel Nicolaus	Set Price Target	Hold	$2.00	Medium
3/19/2018	Stephens	Reiterated Rating	Hold	$2.00	High
9/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$2.00	Low
7/5/2017	Cantor Fitzgerald	Initiated Coverage	Overweight		High
9/19/2016	Bank of America	Set Price Target	Sell	$1.80	N/A
8/22/2016	UBS	Reiterated Rating	Sell		N/A

(Data available from 5/23/2016 forward)

Genesis HealthCare (NYSE:GEN) Earnings History and Estimates Chart

Earnings by Quarter for Genesis HealthCare (NYSE:GEN)

Genesis HealthCare (NYSE:GEN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

Genesis HealthCare (NYSE GEN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/10/2018	Q1 2018	($0.36)	($0.70)	$1.32 billion	$1.3011 billion	View	N/A
3/16/2018	Q4 2017	($0.31)	($0.36)	$1.34 billion	$1.3279 billion	View	N/A
11/8/2017	Q3 2017	($0.30)	($0.36)	$1.3430 billion	$1.3155 billion	View	N/A
8/8/2017	Q2 2017	($0.26)	($0.32)	$1.3660 billion	$1.3413 billion	View	N/A
5/9/2017	Q1 17	($0.25)	($0.50)	$1.4010 billion	$1.3891 billion	View	Listen
3/6/2017	Q4 2016		($0.64)		$1.4029 billion	View	N/A
11/3/2016	Q3	($0.40)	($0.23)	$1.39 billion	$1.4190 billion	View	N/A
8/4/2016	Q2	$0.01	($0.26)	$1.40 billion	$1.44 billion	View	N/A
5/9/2016	Q1	$0.03	($0.01)	$1.43 billion	$1.47 billion	View	N/A
2/22/2016	Q4 2015	($0.05)	($0.05)		$1.4407 billion	View	N/A
11/5/2015	Q315	$0.07	$0.07	$1.42 billion	$1.42 billion	View	N/A
8/6/2015	Q215	$0.09	$0.14	$1.43 billion	$1.41 billion	View	N/A
5/7/2015	Q1 2015	$0.04	$0.07	$1.4291 billion	$1.3430 billion	View	N/A
2/19/2015	Q412	$0.14	$0.14	$209.50 million	$1.19 billion	View	N/A
11/3/2014	Q314	$0.07	$0.13	$208.10 million	$208.60 million	View	Listen
8/11/2014	Q214	$0.06	$0.07	$209.15 million	$207.00 million	View	Listen
5/5/2014	Q114	$0.07	$0.06	$210.39 million	$207.30 million	View	Listen
2/11/2014	Q413	$0.10	$0.06	$215.35 million	$208.30 million	View	Listen
11/4/2013	Q313	$0.10	$0.06	$214.47 million	$212.40 million	View	N/A
8/5/2013	Q2 2013	$0.16	$0.09	$219.58 million	$213.70 million	View	N/A
5/6/2013	Q1 2013	$0.18	$0.10	$222.52 million	$218.90 million	View	N/A
2/11/2013	Q4 2012	$0.19	$0.16	$219.67 million	$219.20 million	View	N/A
11/9/2012	Q312	$0.03	$0.18	$935.06 million		View	N/A
11/5/2012	Q312	$0.20	$0.21	$218.92 million	$216.60 million	View	N/A
8/8/2012		$0.19	$0.18			View	N/A
5/2/2012		$0.19	$0.17			View	N/A
2/13/2012		$0.15	$0.19			View	N/A
10/31/2011		$0.30	$0.32			View	N/A
8/1/2011		$0.31	$0.30			View	N/A
5/3/2011		$0.30	$0.34			View	N/A
2/14/2011		$0.28	$0.31			View	N/A
11/1/2010	Q3 2010	$0.20	$0.25			View	N/A
8/5/2010	Q2 2010	$0.21	$0.24			View	N/A
5/3/2010	Q1 2010	$0.23	$0.24			View	N/A
2/8/2010	Q4 2009	$0.23	$0.25			View	N/A
11/3/2009	Q3 2009	$0.22	$0.25			View	N/A
8/4/2009	Q2 2009	$0.25	$0.25			View	N/A
5/5/2009	Q1 2009	$0.27	$0.29			View	N/A
2/10/2009	Q4 2008	$0.27	$0.28			View	N/A
11/6/2008	Q3 2008	$0.25	$0.26			View	N/A
8/5/2008	Q2 2008	$0.24	$0.24			View	N/A
5/6/2008	Q1 2008	$0.23	$0.23			View	N/A
2/12/2008	Q4 2007	$0.23	$0.21			View	N/A

(Earnings results data provided by Zacks Investment Research)

Genesis HealthCare (NYSE:GEN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Genesis HealthCare (NYSE GEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 58.10%
Institutional Ownership Percentage: 18.70%

Insider Trading History for Genesis HealthCare (NYSE:GEN)

Institutional Ownership by Quarter for Genesis HealthCare (NYSE:GEN)

Genesis HealthCare (NYSE GEN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2017	Joanne Susan Reifsnyder	EVP	Sell	5,269	$1.73	$9,115.37
6/14/2017	Michael Scott Sherman	SVP	Sell	3,903	$1.73	$6,752.19
6/14/2017	Paul David Bach	COO	Sell	6,100	$1.73	$10,553.00
6/14/2017	Stephen Scott Young	VP	Sell	3,799	$1.73	$6,572.27
6/14/2017	Thomas Divittorio	CFO	Sell	6,341	$1.73	$10,969.93
6/7/2017	Daniel Allen Hirschfeld	COO	Sell	2,895	$1.61	$4,660.95
6/7/2017	Joanne Susan Reifsnyder	EVP	Sell	2,383	$1.61	$3,836.63
6/7/2017	Michael Scott Sherman	SVP	Sell	1,824	$1.61	$2,936.64
6/7/2017	Stephen Scott Young	VP	Sell	1,541	$1.61	$2,481.01
6/7/2017	Thomas Divittorio	CFO	Sell	2,900	$1.61	$4,669.00
8/29/2016	Stephen Scott Young	VP	Sell	10,000	$2.38	$23,800.00
6/8/2016	Daniel Allen Hirschfeld	COO	Sell	3,009	$1.72	$5,175.48	488,220
6/8/2016	George V Hager Jr	CEO	Sell	6,031	$1.72	$10,373.32	1,542,780
6/8/2016	Joanne Susan Reifsnyder	EVP	Sell	2,207	$1.72	$3,796.04	286,468
6/8/2016	Michael Scott Sherman	SVP	Sell	1,919	$1.72	$3,300.68	423,220
6/8/2016	Stephen Scott Young	VP	Sell	1,621	$1.72	$2,788.12	172,495
6/8/2016	Thomas Divittorio	CFO	Sell	3,051	$1.72	$5,247.72	509,220
11/12/2015	James V Mckeon	Director	Buy	10,000	$4.15	$41,500.00	29,802
11/11/2015	Thomas Divittorio	CFO	Buy	20,000	$4.34	$86,800.00	387,220
11/14/2013	Boyd Hendrickson	CEO	Sell	48,774	$5.02	$244,845.48	265,430
8/6/2013	Boyd W Hendrickson	CEO	Sell	4,983	$6.03	$30,047.49
8/5/2013	Boyd W Hendrickson	CEO	Sell	24,671	$6.49	$160,114.79
8/2/2013	Boyd W Hendrickson	CEO	Sell	45,346	$6.58	$298,376.68
7/2/2013	Boyd W Hendrickson	CEO	Sell	29,988	$6.46	$193,722.48
7/1/2013	Boyd W Hendrickson	CEO	Sell	28,112	$6.61	$185,820.32
11/1/2012	Boyd W Hendrickson	CEO	Sell	1,567	$8.00	$12,536.00

(Data available from 1/1/2013 forward)

Genesis HealthCare (NYSE GEN) News Headlines

Source:

Date	Headline
	Quorum Health Corporation Announces Leadership Transition www.bizjournals.com - May 21 at 8:28 AM
	FOCUS-A bid to save $300 million at HCR ManorCare, and disrupt U.S. healthcare finance.yahoo.com - May 15 at 8:46 AM
	Free Stock Performance Review on Envision Healthcare and Three More Long-Term Care Facilities Stocks finance.yahoo.com - May 14 at 8:46 AM
	Genesis HealthCare (GEN) Announces Quarterly Earnings Results, Misses Estimates By $0.34 EPS www.americanbankingnews.com - May 12 at 1:35 PM
	Genesis Healthcare's (GEN) CEO George Hager on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 11 at 5:40 PM
	Edited Transcript of GEN earnings conference call or presentation 10-May-18 12:30pm GMT finance.yahoo.com - May 11 at 8:48 AM
	Genesis Healthcare EPS of -$0.70 seekingalpha.com - May 10 at 8:37 AM
	BRIEF-Genesis Healthcare Says Qtrly Loss Per Share Attributable To Co $0.70 www.reuters.com - May 10 at 8:37 AM
	Genesis HealthCare Reports First Quarter 2018 Results finance.yahoo.com - May 10 at 8:37 AM
	Genesis Healthcare: 1Q Earnings Snapshot finance.yahoo.com - May 10 at 8:37 AM
	Interim Report First Quarter 2018 finance.yahoo.com - May 8 at 5:25 PM
	Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma finance.yahoo.com - May 8 at 8:30 AM
	Genesis Healthcare Expects to Release First Quarter 2018 Results on May 10, 2018 finance.yahoo.com - May 8 at 8:30 AM
	Genesis HealthCare (GEN) to Release Quarterly Earnings on Monday www.americanbankingnews.com - May 2 at 8:10 PM
	Form DEF 14A Genesis Healthcare, Inc. For: Jun 06 www.streetinsider.com - April 29 at 8:39 AM
	Form DEFA14A Genesis Healthcare, Inc. www.streetinsider.com - April 29 at 8:39 AM
	What You Must Know About Genomed Spólka Akcyjna’s (WSE:GEN) Major Investors finance.yahoo.com - April 26 at 8:28 AM
	Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting finance.yahoo.com - April 25 at 5:20 PM
	Citigroup Inc., Genesis Healthcare, Molson Coors Brewing Co., Tempur Sealy International, Overstock.com, and 75 Other Companies Join NACD in Q1 2018 globenewswire.com - April 24 at 5:26 PM
	$30M deal: Genesis to sell 51% stake in China subsidiary finance.yahoo.com - April 24 at 5:26 PM
	Stifel Nicolaus Reiterates "$2.00" Price Target for Genesis HealthCare (GEN) www.americanbankingnews.com - April 24 at 4:18 PM
	Reviewing Ensign Group (ENSG) & Genesis HealthCare (GEN) www.americanbankingnews.com - April 24 at 3:32 PM
	Sabra: A Healthcare REIT With Tailwinds And A 10.5% Dividend seekingalpha.com - April 23 at 5:04 PM
	Genesis HealthCare Sells 51% Stake in Chinese Subsidiary GRS-HS to Riswein Health Industry Investment Co., Ltd finance.yahoo.com - April 23 at 5:04 PM
	-$0.31 EPS Expected for Genesis HealthCare (GEN) This Quarter www.americanbankingnews.com - April 20 at 11:28 AM
	Genesis HealthCare (GEN) Cut to Strong Sell at ValuEngine www.americanbankingnews.com - April 18 at 4:44 PM
	Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018 finance.yahoo.com - April 17 at 8:47 AM
	Genesis selling off 2 dozen skilled nursing facilities in Texas finance.yahoo.com - April 12 at 5:23 PM
	Centers Health Care Hires Heidi Hendrix, RN, As New Chief Nursing Officer www.bizjournals.com - April 12 at 8:59 AM
	Genesis Healthcare to divest 23 nursing facilities seekingalpha.com - April 12 at 8:59 AM
	Can Genomed Spólka Akcyjna (WSE:GEN) Improve Your Portfolio Returns? finance.yahoo.com - April 12 at 8:59 AM
	Genesis Energy Limited (NZE:GNE): Time For A Financial Health Check finance.yahoo.com - April 11 at 8:46 AM
	Passing of Genmab A/S’ Annual General Meeting finance.yahoo.com - April 10 at 5:19 PM
	Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab finance.yahoo.com - April 10 at 5:19 PM
	Should You Expect Genomed Spólka Akcyjna (WSE:GEN) To Continue Delivering An ROE Of 29.39%? finance.yahoo.com - April 4 at 4:02 PM
	Capital Increase in Genmab as a Result of Employee Warrant Exercise finance.yahoo.com - April 3 at 5:22 PM
	ValuEngine Downgrades Genesis Healthcare (GEN) to Hold www.americanbankingnews.com - April 3 at 2:58 PM
	Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns www.streetinsider.com - March 26 at 8:36 AM
	Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns - StreetInsider.com www.streetinsider.com - March 24 at 9:01 AM
	Genesis Healthcare riding nursing-home turbulence [Philly.com] www.bloomberg.com - March 22 at 5:25 PM
	Genesis Rehab Services Achieves “World Class” Net Promoter Score finance.yahoo.com - March 22 at 5:25 PM
	Genesis Healthcare (GEN) & Its Competitors Head-To-Head Survey www.americanbankingnews.com - March 22 at 1:38 PM
	Genesis Healthcare (GEN) Rating Reiterated by Stephens www.americanbankingnews.com - March 19 at 9:30 PM
	Should You Be Tempted To Buy Genomed Spólka Akcyjna (WSE:GEN) Because Of Its PE Ratio? finance.yahoo.com - March 19 at 5:08 PM
	Genesis Healthcare, Inc. (GEN) PT Raised to $2 at Stephens - StreetInsider.com www.streetinsider.com - March 19 at 8:36 AM
	Canon Medical Systems’ Aquilion ONE / GENESIS Edition Delivers Full Suite of Acute Stroke Solutions www.bizjournals.com - March 18 at 8:31 AM
	Edited Transcript of GEN earnings conference call or presentation 16-Mar-18 12:30pm GMT finance.yahoo.com - March 17 at 8:42 AM
	Genesis Healthcare (GEN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow seekingalpha.com - March 16 at 6:16 PM
	Genesis Healthcare reports 4Q loss finance.yahoo.com - March 16 at 8:34 AM
	Genesis HealthCare Reports Fourth Quarter and Fiscal Year End 2017 Results finance.yahoo.com - March 16 at 8:34 AM

Genesis HealthCare (NYSE:GEN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Genesis HealthCare (NYSE:GEN) Income Statement, Balance Sheet and Cash Flow Statement

Genesis HealthCare (NYSE GEN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff